Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors

Calgary, Canada (ots/PRNewswire) - Resverlogix Corp.
("Resverlogix" or the "Company") announced today that the Board of
Directors has elected Arthur J. Higgins, CEO of Bayer HealthCare and
Chairman of the Bayer HealthCare Executive Committee, to the Board
effective February 1, 2010.

Mr. Higgins joined Bayer in 2004 as Chairman of the Bayer
HealthCare Executive Committee and in 2006 was named Chairman of the
Board of Management of Bayer HealthCare. Mr. Higgins has played a key
role in driving the success of Bayer HealthCare through a combination
of strong organic growth and key acquisitions, including the (euro)17
billion acquisition of the German pharmaceutical company, Schering
AG, in 2006.

"Arthur Higgins' global leadership experience and exposure to
numerous healthcare markets are just a few of the reasons that he is
a valued addition to the Board," said Donald J. McCaffrey, President
& CEO of Resverlogix. "As we progress through our Phase 2 clinical
trials, we welcome Mr. Higgins' perspective as a strategist and R&D
specialist."

Mr. Higgins was born in Airdrie, Scotland. He studied at
Scotland's Strathclyde University from 1974 to 1978, where he gained
a Bachelor of Science degree in biochemistry.

Mr. Higgins started his career in 1978 in England with
Bristol-Myers. He subsequently worked for Sandoz (1979 to 1984) and
Fisons (1984 to 1987) before moving to Abbott Laboratories in the USA
(1987 to 2001), where he held various positions of increasing
responsibility in the international and domestic divisions,
including a two-year posting in Germany. He was appointed President
of the Pharmaceutical Products Division in Chicago, Illinois, USA,
in 1998. In this position, he was in charge of Abbott's
pharmaceuticals business in the United States with responsibility
for global pharmaceutical research and development.

In 2001, Mr. Higgins was appointed Chairman and CEO of Enzon
Pharmaceuticals headquartered in Bridgewater, New Jersey, USA. In
this function, he also served as Chairman of the Biotech Council of
New Jersey and on the board of the U.S. National Pharmaceutical
Council.

Mr. Higgins represents Bayer in the Executive Committee of the
Pharmaceutical Research and Manufacturers of America (PhRMA), and is
also a member of the Council of the International Federation of
Pharmaceutical Manufacturers and Associations (IFPMA).

From May 2007 until December 2009, Mr. Higgins was President of
the European Federation of Pharmaceutical Industries and Associations
(EFPIA).

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in
the development of novel therapies for important global medical
markets with significant unmet medical needs. The NexVas(TM) PR
program is the Company's primary focus which is to develop novel
small molecules that enhance ApoA-I. These vital therapies address
the burden of atherosclerosis and other important diseases such as
Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral
Artery Disease and other vascular disorders. Resverlogix Corp. trades
on the Toronto Stock Exchange . For further information please visit
http://www.resverlogix.com.

This news release may contain certain forward-looking statements
as defined under applicable Canadian securities legislation,
including our vision to be a leader in the research, development and
commercialization of novel therapeutics that reduce the risk of
cardiovascular disease including atherosclerosis, diabetes,
Alzheimer's disease, Peripheral Artery Disease and other vascular
diseases. These forward-looking statements contained herein that are
not based on historical fact, including without limitation
statements containing the words "believes", "anticipates", "plans",
"intends", "will", "should", "expects", "continue", "estimate",
"forecasts" and other similar expressions. Our actual results,
events or developments could be materially different from those
expressed or implied by these forward-looking statements. We can
give no assurance that any of the events or expectations will occur
or be realized. By their nature, forward-looking statements are
subject to numerous known and unknown risks and uncertainties
including but not limited to those associated with the success of
research and development programs, clinical trial programs including
possible delays in patient recruitment, the regulatory approval
process, competition, securing and maintaining corporate alliances,
market acceptance of the Company's products, the availability of
government and insurance reimbursements for the Company's products,
the strength of intellectual property, financing capability, the
potential dilutive effects of any financing, reliance on
subcontractors and key personnel and additional risk factors
discussed in other documents we file from time to time with
securities authorities, which are available through SEDAR at
http://www.sedar.com. The forward-looking statements contained in
this news release are expressly qualified by this cautionary
statement are made as of the date hereof. The Company disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
The TSX Exchange does not accept responsibility for the adequacy or
accuracy of this news release.

For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1(403)254-9252, Fax:
+1(403)256-8495, Email: Theresa@resverlogix.com; US Investor
Relations: Susan Noonan, Managing Partner, S.A. Noonan
Communications, LLC, Phone: +1(212)966-3650, Email:
susan@sanoonan.com

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: For further information: Theresa Kennedy, VP,
CorporateCommunications, Resverlogix Corp., Phone: +1(403)254-9252,
Fax:+1(403)256-8495, Email: Theresa@resverlogix.com; US Investor
Relations:Susan Noonan, Managing Partner, S.A. Noonan Communications,
LLC, Phone:+1(212)966-3650, Email: susan@sanoonan.com